Kim S - Search Results

1

Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.

Walsh SL, Comer SD, Lofwall MR, Vince B, Levy-Cooperman N, Kelsh D, Coe MA, Jones JD, Nuzzo PA, Tiberg F, Sheldon B, Kim S. Walsh SL, et al. Among authors: kim s. JAMA Psychiatry. 2017 Sep 1;74(9):894-902. doi: 10.1001/jamapsychiatry.2017.1874. JAMA Psychiatry. 2017. PMID: 28655025 Free PMC article. Clinical Trial.

2

Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.

Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ; PRO-814 Study Group. Rosenthal RN, et al. Among authors: kim s. JAMA. 2016 Jul 19;316(3):282-90. doi: 10.1001/jama.2016.9382. JAMA. 2016. PMID: 27434441 Clinical Trial.

3

Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.

Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, Frost M, Tiberg F, Linden M, Sheldon B, Oosman S, Peterson S, Chen M, Kim S. Lofwall MR, et al. Among authors: kim s. JAMA Intern Med. 2018 Jun 1;178(6):764-773. doi: 10.1001/jamainternmed.2018.1052. JAMA Intern Med. 2018. PMID: 29799968 Free PMC article. Clinical Trial.

4

Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.

Frost M, Bailey GL, Lintzeris N, Strang J, Dunlop A, Nunes EV, Jansen JB, Frey LC, Weber B, Haber P, Oosman S, Kim S, Tiberg F. Frost M, et al. Among authors: kim s. Addiction. 2019 Aug;114(8):1416-1426. doi: 10.1111/add.14636. Epub 2019 Jun 3. Addiction. 2019. PMID: 31013390 Free PMC article. Clinical Trial.

5

Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia.

Dammerman R, Kim S, Adera M, Schwarz A. Dammerman R, et al. Among authors: kim s. Clin Pharmacol Drug Dev. 2018 Mar;7(3):298-310. doi: 10.1002/cpdd.428. Epub 2018 Feb 8. Clin Pharmacol Drug Dev. 2018. PMID: 29420868 Clinical Trial.

6

A Phase-1, 6-Month Open-Label, Dose-Ranging Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant.

Dammerman R, Kim S, Adera M, Schwarz A. Dammerman R, et al. Among authors: kim s. Psychopharmacol Bull. 2017 Sep 15;47(4):29-35. Psychopharmacol Bull. 2017. Retraction in: Psychopharmacol Bull. 2018 Jan 15;48(1):154. PMID: 28936006 Retracted. No abstract available.

7

A Phase 1, Open-Label, Single Dose Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant.

Dammerman R, Kim S, Adera M, Schwarz A. Dammerman R, et al. Among authors: kim s. Psychopharmacol Bull. 2017 Sep 15;47(4):36-40. Psychopharmacol Bull. 2017. Retraction in: Psychopharmacol Bull. 2018 Jan 15;48(1):154. PMID: 28936007 Retracted. No abstract available.

8

Comparison of clinical characteristics and outcomes in candidaemia patients with and without COVID-19: a multicentre retrospective study.

Shin SU, Bae S, Cho D, Lee A, Jeong HS, Hwang S, Kim S, Kim M, Kim SE, Kim UJ, Kang SJ, Park KH, Chang HH, Jung SI. Shin SU, et al. Among authors: kim se, kim s. BMC Infect Dis. 2024 Dec 28;24(1):1473. doi: 10.1186/s12879-024-10373-5. BMC Infect Dis. 2024. PMID: 39732640

9

Cognitive and neurodegenerative trajectories of subjective cognitive decline according to baseline biomarkers: Results of the CoSCo study.

Hong YJ, Choi SH, Kim S, Jeong JH, Park KH, Wang MJ, Kang S, Yang DW; CoSCo study group. Hong YJ, et al. Among authors: kim s. Alzheimers Dement. 2024 Dec 28. doi: 10.1002/alz.14473. Online ahead of print. Alzheimers Dement. 2024. PMID: 39732514

10

Enhancing predictive accuracy for antidepressant response in depressive disorders: The additive value of interleukin-1β and interleukin-6 alongside hsCRP.

Kim JM, Kang HJ, Kim JW, Jhon M, Lee JY, Kim SW, Shin IS. Kim JM, et al. Among authors: kim sw. J Affect Disord. 2024 Dec 26:S0165-0327(24)02078-0. doi: 10.1016/j.jad.2024.12.091. Online ahead of print. J Affect Disord. 2024. PMID: 39732400

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

124,079 results

Search Page

Filters